Device Trial Radar · NCT04829994
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
198
Actual
Start
Jul 7, 2021
Primary completion
Sep 30, 2030
Study completion Sep 30, 2035
Sponsor
- Lead sponsor
- Ethicon, Inc.Public (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
Conditions
- Stress Urinary Incontinence
Interventions
InterventionDevice
There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cough Stress Test (CST) Assessment ChangeTime frame: Post-surgery through study completion, approximately 5-10 yrs
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
Duke University
Durham, North Carolina
Institute for Female Pelvic Medicine
North Wales, Pennsylvania
UPMC
Pittsburgh, Pennsylvania
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.